Bellicum Pharmaceuticals (NASDAQ:BLCM) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Thursday.
Other equities analysts also recently issued research reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Wednesday. Raymond James Financial reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. Finally, ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $23.50.
Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up $0.03 during trading hours on Thursday, reaching $8.90. 296,600 shares of the company’s stock traded hands, compared to its average volume of 422,013. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.08 and a quick ratio of 6.08. Bellicum Pharmaceuticals has a twelve month low of $7.41 and a twelve month high of $15.55. The stock has a market capitalization of $295.72, a P/E ratio of -2.98 and a beta of 1.18.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.03. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the prior year, the firm earned ($0.66) EPS. Bellicum Pharmaceuticals’s revenue for the quarter was up 18.2% compared to the same quarter last year. research analysts expect that Bellicum Pharmaceuticals will post -2.93 EPS for the current year.
In other news, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the transaction, the chief financial officer now owns 31,585 shares of the company’s stock, valued at $294,688.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Alan A. Musso sold 6,206 shares of the business’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $9.89, for a total transaction of $61,377.34. The disclosure for this sale can be found here. Insiders sold 23,810 shares of company stock worth $225,657 in the last three months. Insiders own 18.77% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC purchased a new position in shares of Bellicum Pharmaceuticals in the second quarter worth $132,000. Commonwealth Equity Services Inc purchased a new position in shares of Bellicum Pharmaceuticals in the third quarter worth $142,000. Cubist Systematic Strategies LLC purchased a new position in shares of Bellicum Pharmaceuticals in the third quarter worth $164,000. Nationwide Fund Advisors lifted its holdings in shares of Bellicum Pharmaceuticals by 30.4% in the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,620 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Bellicum Pharmaceuticals in the third quarter worth $189,000. 55.28% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Bellicum Pharmaceuticals (BLCM) Downgraded by BidaskClub” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/12/bellicum-pharmaceuticals-blcm-downgraded-by-bidaskclub.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.